Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis

NCT ID: NCT01614405

Last Updated: 2024-11-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2015-08-31

Brief Summary

Patients with primary biliary cirrhosis (PBC) develop progressive liver disease and often require liver transplantation. The cause of disease is unknown. It is thought to occur as a result of an infection in subjects that are more susceptible to disease than others. The investigators found evidence of retrovirus infection in patients with primary biliary cirrhosis. The investigators found that most patients with PBC have evidence of viral infection. Since then the investigators have conducted clinical studies using anti-viral therapy. The investigators found that PBC patients treated with combination anti-retrovirus therapy experienced significant reversal of the disease process. However, the changes were not substantial and the investigators are now looking for better antiviral regimens. Now the investigators have found a mouse model with a similar virus infection that develops a similar biliary disease. Importantly, the investigators found that antiviral therapy blocks the development of the disease in this mouse. The investigators have used this model to find safer and more effective antiviral treatments for patients with PBC. The investigators have now found out that a combination of highly active antiretroviral therapy with Truvada and Kaletra stops disease in the mouse and plan to use this combination to see if it works in patients with PBC.

Detailed Description

6 months therapy with blinded Kaletra and Truvada vs. 6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada

18 month extension study with open label Kaletra and Truvada in patients completing 6 months of therapy with Kaletra and Truvada with biochemical endpoint

Conditions

Primary Biliary Cirrhosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Placebo

Identical Placebo Tablets.

Duration: 6 months therapy with blinded placebo followed by 6 months open label therapy (Truvada and Kaletra). Following, there is an option for an 18-month extension study.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.

TDF/FTC/LPV/r

TDF/FTC/LPV/r

One tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months, or less if adverse events occur.

Duration: 6 months of therapy with the option of open label for additional 18-month extension study.

Group Type: ACTIVE_COMPARATOR

TDF/FTC/LPV/r

Intervention Type: DRUG

one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur

Interventions

TDF/FTC/LPV/r

one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur

Intervention Type: DRUG

Placebo

6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.

Intervention Type: DRUG

Other Intervention Names

Truvada; Tenofovir; Emtricitabine; Kaletra; lopinavir; ritonavir; Truvada; Tenofovir; Emtricitabine; lopinavir; ritonavir

Eligibility Criteria

Inclusion Criteria

1. Patients 18 years old of either sex will be recruited for this study.

2. Elevated ALP after 6 months UDCA therapy ≥ 2 x upper limit of normal or abnormal bilirubin.

3. Positive serum AMA or Liver biopsy histology compatible with PBC.

4. Maintained on UDCA at a dose of 13-15 mg/kg for 6 or more months.

5. Patients must read and sign informed consent form

Exclusion Criteria

1. Subjects with baseline AST or ALT > 5 x ULN.

2. Patients who have altered dose of any medications used to treat PBC (such as UDCA) or the use of colchicine, corticosteroids, azathioprine, chlorambucil, methotrexate, or D-penicillamine within the last 6 months.

3. Advanced liver disease or esophageal varices, INR > 1.2 (upper limit of normal), Albumin < 35 g/L (lower limit of normal), platelets < 120,000/mm3, Childs Pugh class B or C cirrhosis, presence of varices or previous variceal hemorrhage, spontaneous encephalopathy, ascites or need for liver transplantation.

4. Patients with a secondary diagnosis such as HIV, viral hepatitis, drug induced liver injury, extrahepatic biliary obstruction, primary sclerosing cholangitis, metabolic liver diseases or alcoholic liver disease Regular use of more than 30 g of alcohol per day in the last year. Clinically apparent pancreatitis or with a predicted survival of less than 3 years from malignant or other potentially life threatening disease.

5. An ultrasound showing a hepatic mass consistent with hepatocellular carcinoma within the last year in patients with cirrhosis.

6. Previous allergic reaction to study medications.

7. Creatinine clearance less than < 70 mL/min using the Cockcroft Gault equation:

Creatinine clearance (mL/min) = (140 - age) x body wt (Kg) x 0.85 (if female)/serum creatinine in mol/l

8. Pregnancy or breast-feeding a child. Young sexually active patients not using contraception

9. Young sexually active patients not using contraception.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: collaborator

Gilead Sciences

INDUSTRY

Sponsor Role: collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

University of Alberta

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew Mason

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

University of Alberta

Edmonton, Alberta, Canada

Countries

Canada

References

Schembri G, Schober P. Killing two birds with one stone. Lancet. 2011 Jan 1;377(9759):96. doi: 10.1016/S0140-6736(10)61343-8. No abstract available.

Reference Type: BACKGROUND

PMID: 21195252 (View on PubMed)

Other Identifiers

HAART Study

Identifier Type: -

Identifier Source: org_study_id